STAG3

Across TCGA pan-cancer cohorts, STAG3 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated STAG3 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher STAG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STAG3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, LUSC, and UCEC are the cancer types where STAG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.265	0.718	.001	30	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	18	view →
UCEC	DFS	Median	All	0.959	0.824	.007	16	view →
MESO	DFS	Median	II,III,IV	0.058	0.382	<.001	15	view →
STAD	OS	Median	All	0.123	0.669	<.001	14	view →
COAD	OS	Median	IV	0.082	0.659	<.001	9	view →
BRCA	OS	Median	All	0.880	0.963	.009	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.229	0.593	.033	5	view →
READ	DFS	Median	IV	0.255	0.628	.020	3	view →
LIHC	DFS	Median	All	0.153	0.555	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

STAG3–SCLC (OS)

Open the SCLC breakdown →